Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413143 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1RECQLF2 | |
| SCHEMBL4411738 | 0.87 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1F2HCRTR1 | |
| SCHEMBL4421321 | 0.82 | ALDH1A1 (0.46) | RECQL | |
| SCHEMBL4421322 | 0.82 | ALDH1A1 (0.46) | RECQL | |
| SCHEMBL7655323 | 0.79 | ITGAV (0.44) | SLC1A3SLC1A2SLC1A1RECQLF2 | |
| SCHEMBL7655320 | 0.79 | ITGAV (0.44) | SLC1A3SLC1A2SLC1A1RECQLF2 | |
| SCHEMBL7401318 | 0.77 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1F2HCRTR1 | |
| SCHEMBL6861761 | 0.75 | P2RX7 (0.45) | F2F10P2RX7 | |
| SCHEMBL4414191 | 0.75 | MMP2 (0.48) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4414186 | 0.75 | MMP2 (0.48) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313737-B1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-7259159-B2 | Guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1313737-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010168-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176145-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | ADGRF1, VCAM1, ADGRE5 | SLC1A3 2586/4885SLC1A2 2922/4885SLC1A1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.